(Q51136025)

English

Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database.

scientific article published on 4 June 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 March 2018

http://europepmc.org/abstract/MED/24899660

Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database. (English)

1 reference

Europe PubMed Central

30 March 2018

http://europepmc.org/abstract/MED/24899660

0 references

0 references

1 reference

based on heuristic

inferred from title

Maryse Lapeyre-Mestre

3

1 reference

Europe PubMed Central

30 March 2018

http://europepmc.org/abstract/MED/24899660

Jean-Louis Montastruc

4

object named as

Jean-Louis Montastruc

1 reference

Europe PubMed Central

30 March 2018

author name string

Guillaume Moulis

1

1 reference

Europe PubMed Central

30 March 2018

http://europepmc.org/abstract/MED/24899660

Agnès Sommet

2

1 reference

Europe PubMed Central

30 March 2018

http://europepmc.org/abstract/MED/24899660

Association Française des Centres Régionaux de PharmacoVigilance

5

1 reference

Europe PubMed Central

30 March 2018

http://europepmc.org/abstract/MED/24899660

publication date

4 June 2014

1 reference

Europe PubMed Central

30 March 2018

http://europepmc.org/abstract/MED/24899660

1 reference

Europe PubMed Central

30 March 2018

http://europepmc.org/abstract/MED/24899660

53

1 reference

Europe PubMed Central

30 March 2018

http://europepmc.org/abstract/MED/24899660

1864-1871

1 reference

Europe PubMed Central

30 March 2018

http://europepmc.org/abstract/MED/24899660

10

1 reference

Europe PubMed Central

30 March 2018

http://europepmc.org/abstract/MED/24899660

Autoimmune diseases induced by biological agents: a double-edged sword?

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEU214

21 January 2018

Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEU214

21 January 2018

Drugs and autoimmunity--a contemporary review and mechanistic approach

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEU214

21 January 2018

A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF-α agent?

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEU214

21 January 2018

Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEU214

21 January 2018

Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEU214

21 January 2018

A potential event-competition bias in safety signal detection: results from a spontaneous reporting research database in France.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEU214

21 January 2018

Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEU214

21 January 2018

Autoimmune diseases induced by TNF-targeted therapies

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEU214

21 January 2018

Importance of regulatory T cells in the pathogenesis of psoriasis: review of the literature.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEU214

21 January 2018

Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEU214

21 January 2018

Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEU214

21 January 2018

Therapeutic blockade of TNF in patients with SLE-promising or crazy?

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEU214

21 January 2018

Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEU214

21 January 2018

A patient with ankylosing spondylitis who developed infliximab-induced lupus and treated with etanercept

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEU214

21 January 2018

Identifiers

10.1093/RHEUMATOLOGY/KEU214

1 reference

Europe PubMed Central

30 March 2018

http://europepmc.org/abstract/MED/24899660

1 reference

Europe PubMed Central

30 March 2018

http://europepmc.org/abstract/MED/24899660

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51136025&oldid=1250039430"